Mylan’s adalimumab wins CHMP backing

A total of six biosimilar and generic medicines – three apiece – received positive opinions from the European Medicines Agency’s (EMA’s) committee for medicinal products for human use (CHMP) at its July 2018 meeting recommending the granting of marketing authorisations valid throughout the European Union (EU).